Advancing cancer treatment with scalable Targeted Alpha Therapy
Developing selective mTORC1 small-molecule therapies for TSC epilepsy
Developing small-molecule and biologic therapies for kidney diseases
Modular vaccine platform based on immuno-material technology
Harnessing alternative splicing to restore health
First-in-class nanotherapeutics for neurodegenerative diseases
Developing small-molecule therapies for cardiometabolic diseases
Working to end the transplant shortage with Human Compatible xenotransplants
Developing transformational medicines for intractable diseases
Developing one-time in vivo treatments to precisely engineer cells
Modulating the immune system with bacterial peptides
Discovering novel immunology through skin
Developing novel antifungal treatments for invasive fungal infections
Human-first discovery of microbiome therapeutics
Elegantly designed, selectively delivered and activated mRNA 2.0
Repairing neural circuits with transplanted, stem cell-derived neurons
Mining nature to discover new carbohydrates
Developing a new drug class of stapled peptides for oncology
Developing targeted therapies for protein misfolding diseases
Developing a first-in-class pan phosphate transporter inhibitor for chronic kidney disease patients.
Developing tissue-selective RNAi therapies for autoimmune and cardiometabolic diseases
Harnessing the microbiome to treat and prevent inflammatory diseases
Developing next-generation antibody-drug conjugates
Developing treatments for substance use disorders
Developing targeted antibody therapies for cancer
Developing innovative neurodegenerative treatments
